No, invasive aspergillosis and invasive pulmonary aspergillosis are not the same—invasive pulmonary aspergillosis is the most common form of invasive aspergillosis, but invasive aspergillosis encompasses multiple organ manifestations beyond just the lungs.
Understanding the Relationship
Invasive aspergillosis (IA) is the umbrella term for all invasive Aspergillus infections, while invasive pulmonary aspergillosis (IPA) specifically refers to lung involvement. 1
Invasive Aspergillosis Includes Multiple Forms:
- Invasive pulmonary aspergillosis (IPA) - the most common presentation, accounting for the majority of cases
- Invasive sinus aspergillosis - affecting the sinuses
- Tracheobronchial aspergillosis - involving the airways
- CNS aspergillosis - brain and spinal cord infection (carries the highest mortality among all patterns) 1
- Cardiac aspergillosis - endocarditis, pericarditis, myocarditis
- Aspergillus osteomyelitis and septic arthritis
- Ocular aspergillosis - endophthalmitis and keratitis
- Cutaneous aspergillosis
- Aspergillus peritonitis
- Disseminated aspergillosis - involving multiple organs
Clinical Significance
The distinction matters because:
Treatment approaches are similar but not identical: Most forms of invasive aspergillosis follow treatment protocols "similar to invasive pulmonary aspergillosis" 1, but specific modifications exist. For example, CNS aspergillosis requires awareness of drug interactions with anticonvulsants, cardiac aspergillosis requires surgical resection, and ocular infections need ophthalmologic intervention.
IPA can be the source of dissemination: Without adequate therapy, invasive pulmonary aspergillosis may disseminate to the CNS or extend to contiguous intrathoracic structures including great vessels and the heart 1. This progression transforms IPA into broader invasive aspergillosis.
Prognosis varies by site: CNS aspergillosis carries the highest mortality among all patterns of invasive aspergillosis 1, while outcomes for isolated pulmonary disease may be better with early treatment.
Treatment Framework
Primary therapy for IPA is voriconazole (loading dose 6 mg/kg IV every 12 hours for 1 day, then 4 mg/kg IV every 12 hours; oral 200 mg every 12 hours) 1, 2, 1. This same regimen serves as the foundation for most other forms of invasive aspergillosis, with site-specific modifications for surgical intervention or adjunctive measures 1.
Key Pitfalls to Avoid:
- Don't assume all Aspergillus infections are invasive: Chronic pulmonary aspergillosis, aspergilloma, and allergic forms exist as separate entities
- Don't miss extrapulmonary involvement: Always assess for dissemination in patients with IPA, particularly to the CNS in severely immunocompromised hosts
- Don't delay treatment: Early initiation of antifungal therapy while diagnostic evaluation is conducted is critical, as invasive pulmonary aspergillosis can progress to devastating hemorrhagic infarction or disseminated disease 1
The terminology matters for accurate communication, appropriate diagnostic workup, and recognition that pulmonary disease may herald or coexist with involvement of other organs requiring additional interventions beyond antifungal therapy alone.